Homegrown COVID-19 pill gets regulatory approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-07-25 19:48
Share
Share - WeChat
China's top drug regulator said on Monday it has granted conditional approval for a homegrown oral pill to be used to treat COVID-19.
Azvudine, developed by Genuine Biotech Co Ltd based in Henan province, was first approved to treat HIV/AIDS patients on July 20 last year, according to the National Medical Products Administration.
The approval clears the way for the pill to be used for adults with moderate COVID-19 symptoms, the administration said in a notice released on its official website.
- 10 dead and 84 injured in explosion at steel plant
- China unveils flexible urban planning rules to improve lives, foster new industries
- Ex–China Construction Bank executive gets 18 years for bribery, loan violations
- First batch of eco-friendly pioneer zones for construction of beautiful countryside unveiled
- Woodpeckers, finches captured in Jilin winter scenes
- Mainland reiterates 1992 Consensus as foundation for resuming cross-Strait dialogue
